Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination With Capecitabine in Patients With Solid Tumors

NCT00121277 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT00121277
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00121277 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination With Capecitabine in Patients With Solid Tumors
Lead sponsor
University Health Network, Toronto
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2005
Completion date
Not reported
Enrollment
28 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

unspecified adult solid tumor, protocol specific